Wednesday, July 12, 2023
Gustave Roussy, Europe's leading cancer center, and THERYQ, a French medical technology company specializing in particle accelerators and radiotherapy systems, have announced a strategic partnership for the deployment and evaluation of FLASH technology in radiotherapy. As part of this collaboration, THERYQ has installed the first clinical FLASH radiotherapy machine in France at Gustave Roussy's radiotherapy department. The machine is specifically designed for the treatment of superficial tumors.
The FLASHKNiFE® machine developed by THERYQ utilizes electron-based technology to deliver high doses of radiation at an incredibly fast rate, allowing treatment to be completed within milliseconds. This innovative technique has shown promising results in preclinical studies by effectively targeting tumor cells while minimizing damage to surrounding healthy tissues. The rapid irradiation time also ensures greater precision and control in targeting tumors by eliminating organ or tumor movement.
Gustave Roussy will be the first center in France to host THERYQ's FLASH radiotherapy machine. Before its routine use, a clinical study will be conducted to evaluate the effectiveness of FLASH radiotherapy in patients with superficial tumors, such as skin cancer. The results of this study have the potential to revolutionize the management of skin cancers and pave the way for advancements in the treatment of solid tumors.
The introduction of this state-of-the-art FLASH radiotherapy equipment marks a significant technological advancement compared to current methods. The reduced treatment sessions and the ability to minimize radiation-induced side effects offer the potential for more effective and better-tolerated treatments. Both Gustave Roussy and THERYQ are excited about this collaboration and the potential impact it holds for significantly improving cancer treatment and patient care.
Source: prnewswire.com
